ELV001
Rheumatoid Arthritis (inadequate response to MTX and TNF inhibitors)
Key Facts
About Elevara Medicines
Elevara Medicines is pioneering a novel, non-immunosuppressive approach to treating rheumatoid arthritis by directly targeting fibroblast-like synoviocytes (FLS), a key driver of disease pathology. Its lead asset, ELV001, is an oral CDK4/6 inhibitor currently in a global Phase 2b trial (START-SYNERGY) as an add-on therapy for patients with an inadequate response to TNF inhibitors and methotrexate. The company is backed by a $70 million Series A financing from top-tier European life science investors and is led by a team with deep expertise in rheumatology and drug development. Elevara's strategy aims to break the 'ditch and switch' paradigm in RA by providing a synergistic therapy that elevates the efficacy of existing standard-of-care treatments.
View full company profile